19
Clinical insight
P R O B E
• V o l . L I I I • N o . 3 • A p r – J u n 2 0 1 4
Other studies have indicated the
pharmacological activities of the
ingredients of Cystone. Herbs like
Didymocarpus pedicellata
has been
shown to have diuretic activity.
65
Another plant,
Saxifraga ligulata
, is
reported to have active principles like
afzelechin and bergenin. Afzelechin
and bergenin are tannins and possess
astringent properties, which make
them effective antimicrobial agents.
Bergenin is a known diuretic and is
helpful in dissolving kidney stones.
66,67
The roots of
Rubia cordifolia
contain
ruberythic acid, which has been
proved to dissolve oxalate stones
present in the urinary tract, thereby
facilitating their expulsion without
recourse to surgery.
68-70
It also
possesses astringent, antibacterial,
and anti-inflammatory actions.
The oil from the roots of
Cyperus
scariosus
has been found to exhibit
anti-inflammatory properties.
71,72
Studies conducted on the extracts of
C scariosus
were found to have potent
antioxidant activity.
Achyranthes
aspera
has potent anti-inflammatory,
astringent, demulcent, and diuretic
activity.
73
Onosma bracteatum
is
known to have diuretic action. It
regulates urine output, acts as a
demulcent, and provides soothing
action. It is useful in bladder irritation
and is a spasmolytic.
74
Hajrul yahood
bhasma
75
is useful as a diuretic and
a lithotropic. It is given in retention
of urine and in other diseases of the
urinary tract. Shilajeet (purified)
treats urinary disorders due to its
tonic activity.
76
It is probable that
these ingredients may be producing an
additive activity to bring about relief
in urolithiasis.
In spite of large number of clinical
trials conducted, a number of lacunae
(few controlled trials and lack of dose-
dependent studies) still exist. These
studies if carried out will go a long
way in defining the role of Cystone in
the management of urolithiasis.
Conclusion
The outcome of 50 clinical studies
indicated that Cystone is useful in
the management of urolithiasis as
revealed by the clearance of calculi,
symptomatic relief, increased urine
volume, and reduction in the stone
forming constituents in urine with
negligible adverse effects.
References
1.
Green S.
Singapore Med J
. 2005;46(6):
270.
2.
L’Abbe KA , et al.
Ann Intern Med
.
1987;107(2):224–233.
3.
Dave HD. Clinical observations on
the use of “Cystone” tablets in the
treatment of urolithiasis. In:
Medical
Digest
; 764.
4.
Benker YG. Oral treatment for
urolithiasis. In:
Medical Digest
; 1954:
441.
5.
Vakil JN.
Indian Practit
. 1956;281.
6.
Rai SC.
Curr Med Pract
. 1960;9:484.
7.
Subramaniam R.
The Antiseptic
.
1961;(58)2:103.
8.
Pantulu KP.
Capsule
. 1967;98.
9.
Goel KG.
Probe
. 1968;VII(4):147–148.
10.
Vagh VT.
The Indian Practit
.
1968;303–304.
11.
Saronwala KC.
The Antiseptic
.
1973;7:467–469.
12.
Trivedi BT.
Probe
. 1974;XIII(3):134–
135.
13.
Patel GT.
The Antiseptic
. 1974;
71(8):452.
14.
Gupta PD.
Probe
. 1976;XV(2):108–
112.
15.
Sengupta
BR.
Probe
.
1978;XVII(3):239–241.
16.
Kumar P.
Probe
. 1979;XVIII(2):89–93.
17.
Kishore B.
Capsule
. 1979;3:55.
18.
Mukherjee
M.
Probe
.
1979;XVIII(2):82–85.
19.
Singh NB.
Probe
. 1980;XIX(3):204–
206.
20.
Dhir BB.
Capsule
. 1980;7:150.
21.
Mujumdar S, et al.
Med Surg
.
1980;5(6):5–6.
22.
Ghose A.
Probe
. 1980;XIX(4):270–274.
23.
Prasad RR.
The Indian Practit
.
1980;685–690.
24.
Misgar MS.
Probe
. 1981;XX(3):199–
201.
25.
Subbiah N.
Capsule
. 1981;4:83.
26.
Kulkarni SL.
Capsule
. 1981;2:35.
27.
Misgar.
Curr
Med
Pract
.
1982;26(11):327.
28.
Nagar P.
Capsule
. 1982;6:132.
29.
Chatterjee
BN.
Probe
.
1982;XXII(1):27–30.
30.
Sharma BM.
Probe
. 1982;XXI(4):257–
260.
31.
Singh
PP.
The
Antiseptic
.
1983:30(5):234.
32.
Singh PP.
Arch Med Pract
. 1983;2:43–
48.
33.
Singh PP, et al.
Indian Drugs
.
1983;7:264.
34.
Singh
PP,
et
al.
Probe
.
1984;XXIII(2):78–81.
35.
Pendse AK, et al.
Asian Med J
.
1984;2:136–140.
36.
Chaudhry K.
Capsule
. 1984;2:30.
37.
Singh D.
Probe
. 1984;XXIII(2):82–83.
38.
Tripathi K, et al.
Probe
.
1984;XXIII(2):87–89.
39.
Singh PP.
Karnataka Med J
.
1984;51:65–67.
40.
Singh PP.
Asian Med J
. 1985;28(4):261–
265.
41.
Setia AP.
Probe
. 1985;XXIV(4):240–
242.
42.
Kekade SR.
Probe
. 1985;XXIV(3):167–
168.
43.
Garg SK.
Probe
. 1985;XXIV(2):119–121.
44.
Singh, PP.
The Indian Practit
.
1986;4:377–381.
45.
Gajjar AK.
Probe
. 1987;XXVI(2):127–
128.
46.
Sengupta S.
Med Surg
. 1987;27(8):7–9.
47.
Patnaik S.
Capsule
. 1987:7.
48.
Verma
D.
The
Antiseptic
.
1989;86(5):257–259.
49.
Srivastava RK.
Curr Med Pract
.
1991;35(4):89–94.
50.
Sharma S, et al.
Probe
. 1992;XXXII(1):
20–23.
51.
Marya SKS.
Med Surg
. 1983;21–23.
52.
Bhatnagar V, et al.
Med Update
.
2004;11(11):47–54.
53.
Clendening L. Source Book of Medical
History. New York: Dove Publications.
1942:14–18.
54.
Pak CYC.
Miner Electrol Metab
.
1987;13:257.
Karamakar D, et al.
Meta-analysis of Efficacy and Safety Studies of Cystone
